Back to search

Switzerland· 34497125

Angina MCC Streuli

A cetylpyridinium product containing cetylpyridinii chloridum, lidocaini hydrochloridum monohydricum, levomentholum, registered in Switzerland and dispensed under Swissmedic category D, on the national reimbursement list. The same ATC class is registered in 4 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat D (Swissmedic)ATC R02AA06

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedAngina MCC StreuliATCR02AA06REGISTER NO.34497125PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Cetylpyridinium is registered in 4 of 19 countries.

Countries holding a registration under ATC R02AA06 (cetylpyridinium), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 3 of them publish a price we can compare per daily dose

Cetylpyridinium · ATC R02AA06

4 / 19 countries

  • Canada
  • Czechiaprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
cetylpyridinii chloridum, lidocaini hydrochloridum monohydricum, levomentholum
Manufacturer
—
Country
Switzerland (CH)
ATC code
R02AA06
ATC class
Cetylpyridinium
Swissmedic category
D
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680344971254
    50 Stk
    CHF 5.05

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for cetylpyridinium.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cetylpyridinium · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • Hyaluronic acidM09AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/06116aa2-97cf-476d-8b68-9c5d6ccefe94
GET /v1/drugs/06116aa2-97cf-476d-8b68-9c5d6ccefe94?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "cetylpyridinii chloridum 1.25 mg + lidocaini hydrochloridum monohydricum 1 mg + levomentholum 4 mg",
  "valid_from": "1987-03-15",
  "limitations": null,
  "galenic_form": "Lutschtabl",
  "therapeutic_area": null,
  "sl_inclusion_date": "1987-03-15",
  "self_retention_pct": 10
}

See everything about cetylpyridinium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.